This approval marked the first oral GLP-1 RA indicated specifically for obesity, creating a new option for patients and clinicians who prefer or require non-injectable therapies, in contrast to Rybelsus, an oral semaglutide approved for the treatment of type 2 diabetes
Martnez-Herrera B-E, Muoz-Garca M-G, Jos-Ochoa L-L, Quiroga-Morales L-A, Cervntes-Gonzlez L-M, Mireles-Ramrez M-A, et al
The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)
The median follow-up duration was 1 year (IQR: 0.52 years), with key findings including a median weight loss of 11.7 kg and a median BMI at the most recent follow-up of 31.2 kg/m 2 , reflecting a median reduction of 3.7 kg/m 2
And when your blood sugar gets low enough, your body ratchets up a process called glycogenesis, which breaks down tissue, including fat, to maintain blood sugar
Last reviewed: June 27, 2026 Last updated: June 27, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
